FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2004608451> ?p ?o ?g. }

• W2004608451 endingPage "702" @default.
• W2004608451 startingPage "697" @default.
• W2004608451 abstract "Nifedipine (NFP) is an anti-hypersensitive drug and a well-known substrate of cytochrome P450 3A4 (CYP3A4), while cyclosporine (CSP) is a potent p-glycoprotein (P-gp) inhibitor. P-gp is a drug transporter, which determines the absorption and bioavailability of many drugs that are substrates for P-gp. Drugs that induce or inhibit P-gp may have a profound effect on the absorption and pharmacokinetics (PK) of drugs transported by P-gp within the body, possibly compromising their bioavailability. But the role of P-gp in the NFP efflux and its impact on PK profile is not known. Hence in our present study we attempted to investigate the effect of CSP on oral absorption and PK of NFP. Rhodamine 123 (Rho 123), a known P-gp substrate was used as a positive control. Male Wistar rats (350–400 g) were used for the study. Rats were divided into 4 groups (n = 6 each); one group was treated with vehicle (cremophor) followed by NFP (0.2 mg/kg; i.v. bolus) and the other group with CSP (10 mg/kg; i.v.) followed by NFP. Group 3 and 4 were treated with vehicle (cremophor) followed by Rho 123 (0.2 mg/kg, i.v.) and CSP (10 mg/kg; i.v.) followed by Rho 123 (0.2 mg/kg, i.v.) respectively. The blood samples were collected at 0, 5, 10, 15, 30, 60, 90, 120, 180 and 240 min after NFP administration. NFP concentrations in plasma were analyzed by LC–MS–MS and Rho 123 was analyzed by fluorimetric detector. NFP efflux was significantly decreased in CSP treated rats (49.1% decrease, P < 0.05), while NFP concentration in plasma were not changed. However the decrease in NFP efflux did not show any significant changes in NFP PK parameters (Tmax; 2.0 vs. 2.5 min, Cmax; 0.084 vs. 0.076 μg/ml, T1/2; 84.0 vs. 91.4 min, AUC0–t; 4.183 vs. 3.467 μg h/ml, AUC∞; 5.915 vs. 4.769 μg h/ml, AUMC0–t; 224.073 vs. 173.063 μg h/ml, AUMC∞; 776.871 vs. 575.038 μg h/ml, MRT0–t; 53.608 vs. 49.538 μg h/ml, MRT∞; 118.194 vs. 115.246 μg h/ml, CLtot; 0.0375 vs. 0.0433 l/h, Vdss; 3.999 vs. 4.641 l in NFP alone vs. CSP + NFP groups respectively). Thus the results indicate that NFP would belong to a group of P-gp substrate. The decrease in efflux of NFP by CSP, through inhibition of P-gp, into the intestinal lumen did not show any impact on PK. This could be due to the activity of other transporters and/or CYP3A4 may have more limiting role than P-gp on NFP metabolism and disposition that is why inhibiting P-gp did not lead to increase the bioavailability and PK alterations." @default.
• W2004608451 created "2016-06-24" @default.
• W2004608451 creator A5007108013 @default.
• W2004608451 creator A5022238647 @default.
• W2004608451 creator A5032422017 @default.
• W2004608451 creator A5037578229 @default.
• W2004608451 creator A5041858502 @default.
• W2004608451 creator A5076002605 @default.
• W2004608451 creator A5091761204 @default.
• W2004608451 date "2009-11-01" @default.
• W2004608451 modified "2023-10-16" @default.
• W2004608451 title "Effect of cyclosporine on drug transport and pharmacokinetics of nifedipine" @default.
• W2004608451 cites W1964470226 @default.
• W2004608451 cites W1975378193 @default.
• W2004608451 cites W1987390177 @default.
• W2004608451 cites W1990836565 @default.
• W2004608451 cites W2002449738 @default.
• W2004608451 cites W2005328285 @default.
• W2004608451 cites W2024632508 @default.
• W2004608451 cites W2032417894 @default.
• W2004608451 cites W2032811036 @default.
• W2004608451 cites W2034388219 @default.
• W2004608451 cites W2035019909 @default.
• W2004608451 cites W2049147399 @default.
• W2004608451 cites W2051508505 @default.
• W2004608451 cites W2056698306 @default.
• W2004608451 cites W2061155379 @default.
• W2004608451 cites W2065324366 @default.
• W2004608451 cites W2077510533 @default.
• W2004608451 cites W2078877172 @default.
• W2004608451 cites W2082437431 @default.
• W2004608451 cites W2095097807 @default.
• W2004608451 cites W2102458361 @default.
• W2004608451 cites W2105934299 @default.
• W2004608451 cites W2111067261 @default.
• W2004608451 cites W2121167726 @default.
• W2004608451 cites W2125748363 @default.
• W2004608451 cites W2136564762 @default.
• W2004608451 cites W2153413276 @default.
• W2004608451 cites W2155315199 @default.
• W2004608451 cites W2190657765 @default.
• W2004608451 cites W2319670801 @default.
• W2004608451 cites W4256478035 @default.
• W2004608451 cites W970450957 @default.
• W2004608451 cites W2074816934 @default.
• W2004608451 doi "https://doi.org/10.1016/j.biopha.2009.04.031" @default.
• W2004608451 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19819100" @default.
• W2004608451 hasPublicationYear "2009" @default.
• W2004608451 type Work @default.
• W2004608451 sameAs 2004608451 @default.
• W2004608451 citedByCount "25" @default.
• W2004608451 countsByYear W20046084512012 @default.
• W2004608451 countsByYear W20046084512013 @default.
• W2004608451 countsByYear W20046084512014 @default.
• W2004608451 countsByYear W20046084512015 @default.
• W2004608451 countsByYear W20046084512016 @default.
• W2004608451 countsByYear W20046084512017 @default.
• W2004608451 countsByYear W20046084512019 @default.
• W2004608451 countsByYear W20046084512022 @default.
• W2004608451 countsByYear W20046084512023 @default.
• W2004608451 crossrefType "journal-article" @default.
• W2004608451 hasAuthorship W2004608451A5007108013 @default.
• W2004608451 hasAuthorship W2004608451A5022238647 @default.
• W2004608451 hasAuthorship W2004608451A5032422017 @default.
• W2004608451 hasAuthorship W2004608451A5037578229 @default.
• W2004608451 hasAuthorship W2004608451A5041858502 @default.
• W2004608451 hasAuthorship W2004608451A5076002605 @default.
• W2004608451 hasAuthorship W2004608451A5091761204 @default.
• W2004608451 hasConcept C109650736 @default.
• W2004608451 hasConcept C112705442 @default.
• W2004608451 hasConcept C121332964 @default.
• W2004608451 hasConcept C125287762 @default.
• W2004608451 hasConcept C133936738 @default.
• W2004608451 hasConcept C178790620 @default.
• W2004608451 hasConcept C181389837 @default.
• W2004608451 hasConcept C185592680 @default.
• W2004608451 hasConcept C24890656 @default.
• W2004608451 hasConcept C2777056448 @default.
• W2004608451 hasConcept C2778589691 @default.
• W2004608451 hasConcept C2778707650 @default.
• W2004608451 hasConcept C2779066535 @default.
• W2004608451 hasConcept C2780035454 @default.
• W2004608451 hasConcept C501593827 @default.
• W2004608451 hasConcept C519063684 @default.
• W2004608451 hasConcept C526171541 @default.
• W2004608451 hasConcept C55493867 @default.
• W2004608451 hasConcept C62231903 @default.
• W2004608451 hasConcept C71924100 @default.
• W2004608451 hasConcept C97320921 @default.
• W2004608451 hasConcept C98274493 @default.
• W2004608451 hasConceptScore W2004608451C109650736 @default.
• W2004608451 hasConceptScore W2004608451C112705442 @default.
• W2004608451 hasConceptScore W2004608451C121332964 @default.
• W2004608451 hasConceptScore W2004608451C125287762 @default.
• W2004608451 hasConceptScore W2004608451C133936738 @default.
• W2004608451 hasConceptScore W2004608451C178790620 @default.
• W2004608451 hasConceptScore W2004608451C181389837 @default.
• W2004608451 hasConceptScore W2004608451C185592680 @default.

• next